news
Roche invests for the future in its Basel site
22 October 2014 | By Roche
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development...
List view / Grid view
Roche
news
Roche delivers solid sales growth for the first nine months of 2014
16 October 2014 | By Roche
Roche announce Q3 2014 results...
news
FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States
16 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis in the United States...
news
FDA grants Priority Review for Lucentis in diabetic retinopathy
9 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans...
news
Roche purchases shares in tender offer for InterMune, Inc.
30 September 2014 | By Roche
Roche and InterMune, Inc. announced that Roche’s wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash...
news
Roche’s Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
30 September 2014 | By Roche
Roche announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer...
news
Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab)
29 September 2014 | By Roche
Roche has announced the first combination data of its investigational cancer immunotherapy MPDL3280A and Avastin in untreated patients with mRCC...
news
Roche’s investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone
29 September 2014 | By Roche
Roche announced positive data from the coBRIM Phase III study...
news
Roche launches Global Access Program for HIV viral load testing
26 September 2014 | By Roche
Roche announced the launch of a new Global Access Program for HIV viral load testing...
news
Roche’s Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies
25 September 2014 | By Roche
Roche announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival...
news
Roche investing in Kaiseraugst
18 September 2014 | By Roche
Roche announced that it is planning to invest more than half a billion Swiss francs in buildings and infrastructure projects at Kaiseraugst...
news
Roche to present latest oncology advances during ESMO 2014 Congress
17 September 2014 | By Roche
Roche announced that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain...
news
Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA)
15 September 2014 | By Roche
Roche announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy, the advanced form of age-related macular degeneration, a progressive condition which can result in blindness...
news
Roche’s RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA)
8 September 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated with methotrexate...
news
Roche announces change in Board of Directors
4 September 2014 | By Roche
Roche announced that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as Chief Executive Officer at Calico...
